Angelo Aguilar
Assoicate Research Scientist
Internal Medicine
Internal Medicine-Hematology/Oncology
1600 Huron Parkway, NCRC Bldg. 520, RM G343
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Angelo Aguilar
Associate Research Scientist
  • Qualifications
  • Recent Publications
    • Qualifications
    • Postdoctoral Research Fellow
      University of Michigan–Ann Arbor, Internal Medicine - Hematology/Oncology, 2014
    • PhD
      Kansas State University, Department of Organic Chemistry, Manhattan, 2008
    • BSc
      Regis University, Department of Chemistry, Denver, 2001
    • Associate of Science in Chemistry
      Saint John's Junior College, Belize, 1999
    Recent Publications See All Publications
    • Journal Article
      Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
      Wang C, Wang M, Wang Y, Rej RK, Aguilar A, Xu T, Bai L, Tošović J, McEachern D, Li Q, Sarkari F, Wen B, Sun D, Wang S. J Med Chem, 2024 Aug 22; 67 (16): 14125 - 14154. DOI:10.1021/acs.jmedchem.4c00971
      PMID: 39132814
    • Journal Article
      Targeting MDM2 for the development of a new cancer therapy: progress and challenges
      Aguilar A, Thomas JE, Wang S. Medicinal Chemistry Research, 2023 Jul 1; 32 (7): 1334 - 1344. DOI:10.1007/s00044-023-03102-1
    • Journal Article
      Therapeutic Strategies to Activate p53.
      Aguilar A, Wang S. Pharmaceuticals (Basel), 2022 Dec 24; 16 (1): DOI:10.3390/ph16010024
      PMID: 36678521
    • Patent
      Heterocyclyl-piperidinediones as cereblon ligands and their preparation
      Wang S, Xu T, Wu D, Chen Z, Han X, Xiang W, Rej R, Aguilar A, Bai L.
    • Journal Article
      Strategies for the drug discovery and development of taxane anticancer therapeutics.
      Wang C, Aguilar A, Ojima I. Expert Opin Drug Discov, 2022 Nov; 17 (11): 1193 - 1207. DOI:10.1080/17460441.2022.2131766
      PMID: 36200759
    • Patent
      MDM2 protein Degraders
      Wang S, Li Y, YANG J, Aguilar A, Zhou B, HU J, Xu F, Rej R, Han X. 2021 Dec 7;
    • Patent
      MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER
      Liu T, Sui Z, Zhou S, Ji J, Wang S, Zhang M, Aguilar A, Zhou H, Xu F, Huang L, Stuckey J, Kirchhoff P.
    • Journal Article
      Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
      Zhang M, Aguilar A, Xu S, Huang L, Chinnaswamy K, Sleger T, Wang B, Gross S, Nicolay BN, Ronseaux S, Harvey K, Wang Y, McEachern D, Kirchhoff PD, Liu Z, Stuckey J, Tron AE, Liu T, Wang S. J Med Chem, 2021 Jul 22; 64 (14): 10333 - 10349. DOI:10.1021/acs.jmedchem.1c00789
      PMID: 34196551